EGFR and hepatocellular carcinoma: In all cells harboring HCC-derived EGFR mutants, the LC3-II level was also clearly increased after 48 h of treatment with 5 μM erlotinib; the increment detected in cells harboring HCC-derived EGFR mutants was less and occurred later than in cells harboring L858R.